Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
Filing tables
Filing exhibits
- 20-F Annual report (foreign)
- 2.3 Description of Securities
- 4.11 Share Sale and Purchase Agreement Between Incannex Healthcare Limited and the Sellers of Apirx Pharmaceutical USA, LLC, Dated May 12, 2022
- 8.1 List of Subsidiaries of Registrant
- 12.1 Certification
- 12.2 Certification
- 13.1 Certification
- 13.2 Certification
- 15.1 Letter to Securities and Exchange Commission from Withum Smith+brown, PC Dated October 28, 2022
- Download Excel data file
- View Excel data file
IXHL similar filings
Filing view
External links
Exhibit 15.1
October 28, 2022
Office of the Chief Accountant
Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
Ladies and Gentlemen:
We have read the statements made by Incannex Healthcare Limited (the “Company”) in Form 20-F dated October 28, 2022. We agree with the statements concerning our Firm in such Form 20-F; we are not in a position to agree or disagree with the Company’s statements that the audit committee decided to engage PKF Brisbane Audit to serve as the Company’s new independent registered public accounting firm and related statements contained therein.
Very truly yours, | |
/s/ WithumSmith+Brown, PC | |
New York, New York |